Company: DAWN
Filing Date: 2025-04-11
Form Type: DEF 14A
Source: 0001140361-25-013462
Chunk: 68

Company: Day One Biopharmaceuticals, Inc.
Filing Date: 2025-04-11
Form: DEF 14A
Chunk 68
---
 be permitted to directors, executive officers or persons controlling us, we have been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. Rule 10b5-1 Sales Plans Certain of our directors and executive officers have adopted written plans, known as Rule 10b5-1 plans, in which they have contracted with a broker to buy or sell shares of our common stock on a periodic basis. Under a Rule 10b5-1 plan, a broker executes trades pursuant to parameters established by the director or executive officer when entering into the plan, without further direction from them. The director or executive officer may amend or terminate the plan in specified circumstances. 53

TABLE OF CONTENTS

EQUITY COMPENSATION PLAN INFORMATION The following table presents information as of December 31, 2024 with respect to compensation plans under which shares of our common stock may be issued.

| Plan category                                                 |     |     Number of 
    securities 
  to be issued 
          upon 
   vesting and 
      exercise 
            of 
   outstanding 
    securities 
           (#) |     |   Weighted- 
     average 
    exercise 
       price 
          of 
 outstanding 
     options 
      ($)(1) |     |    Number of 
   securities 
    remaining 
    available 
   for future 
     issuance 
        under 
       equity 
 compensation 
        plans 
   (excluding 
   securities 
 reflected in 
      column) 
          (#) |
| Equity compensation plans approved by security holders        |     | 13,651,301(2) |     |       16.38 |     | 5,260,151(3) |
| Equity compensation plans not approved by security holders(4) |     |       332,702 |     |       21.14 |     |      643,600 |
| Total                                                         |     |    13,984,003 |     |             |     |    5,903,751 |

| (1) | The weighted-average exercise price does not reflect the shares that will be issued in connection with the settlement of RSUs, since RSUs have no exercise price. |

| (2) | Excludes purchase rights accruing under the 2021 Employee Stock Purchase Plan (“2021 ESPP”). |

| (3) | As of December 31, 2024, there were 2,838